drugset / Trial / NCT04381325
A Study of MSB0254 Injection in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study was an open, multi-dose dose escalation phase I clinical study to evaluate the safety, tolerability and PK characteristics of MSB0254 in patients with locally advanced or metastatic solid tumors, and to preliminarily measure its anti-tumor efficacy.
Timeline
- Start
- 2020-04-01
- Primary completion
- 2022-06-08
- Completion
- 2022-06-08
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSB0254 | Unknown | 4 mg/kg | Intravenous |
| Subject | MSB0254 | Unknown | 8 mg/kg | Intravenous |
| Subject | MSB0254 | Unknown | 12 mg/kg | Intravenous |
| Subject | MSB0254 | Unknown | 16 mg/kg | Intravenous |
| Subject | MSB0254 | Unknown | 20 mg/kg | Intravenous |